mortality/aging
• STZ-treated mice subjected to myocardial infarction exhibit resistance to increased mortality compared with similarly treated wild-type mice
• however, survival is normal in mice not treated with STZ
|
cardiovascular system
• STZ-treated mice subjected to myocardial infarction (MI) exhibit improved intrinsic sinus node function compared with similarly treated wild-type mice
|
• streptozotocin (STZ)-treated mice subjected to myocardial infarction (MI) exhibit resistance to increased mortality with increased resting heart rate, reduced episodes of very low heart rate, improved activity-related heart rate increases, improved intrinsic sinus node function, reduced apoptosis in the sinoatrial node and reduced fibrosis compared with similarly treated wild-type mice
• however, survival is normal in mice not treated with STZ and STZ mice subjected to MI exhibit normal left ventricle contractile function and volume
|
homeostasis/metabolism
• streptozotocin (STZ)-treated mice subjected to myocardial infarction (MI) exhibit resistance to increased mortality with increased resting heart rate, reduced episodes of very low heart rate, improved activity-related heart rate increases, improved intrinsic sinus node function, reduced apoptosis in the sinoatrial node and reduced fibrosis compared with similarly treated wild-type mice
• however, survival is normal in mice not treated with STZ and STZ mice subjected to MI exhibit normal left ventricle contractile function and volume
|
cellular
• in the sinoatrial node of STZ-treated mice subjected to myocardial infarction
|
• increased reactive oxygen species in right atrial tissue after streptozotocin (STZ) treatment
|